These results suggest that the combination of SPPARMα and SGLT2 inhibitors has therapeutic potential for NASH and NASH-related HCC via reduction of ER stress-induced liver injury. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.